Clinical Trials

Find a Trial

Trial Summary

Protocol No.PHO-LILLY-CROOP-ADVL1416
StatusOPEN TO ACCRUAL
Principal InvestigatorCroop, James
ScopeNational
PhasePhase I
Age GroupChildren
TitleA PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
DescriptionThe main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Part A: participants with recurrent or refractory non-CNS solid tumors
  • Part B: participants with recurrent or refractory CNS tumors
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
  • Riley Hospital for Children
Treatment TypeTreatment
ContactMelissa Lee, Phone: +1 317-944-4281
Pager: 312-1228
Email: mellee@iu.edu